Aeolus Pharmaceuticals Inc (AOLS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
26361 CROWN VALLEY PARKWAY, SUITE 150 MISSION VIEJO, CA 92691 |
| State of Incorp. | DE |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2017 Q3 | 3/31/2017 Q2 | 12/31/2016 Q1 | 9/30/2016 Q4 | 6/30/2016 Q3 | 3/31/2016 Q2 | 12/31/2015 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 981 | 1,895 | 3,155 | 3,756 | 4,509 | 5,444 | |||
| Cash and cash equivalents | 981 | 1,895 | 3,155 | 3,756 | 4,509 | 5,444 | |||
| Receivables | 603 | 544 | 750 | 742 | 1,366 | 871 | |||
| Other undisclosed current assets | 149 | 178 | 230 | 343 | 353 | 66 | |||
| Total current assets: | 1,733 | 2,617 | 4,135 | 4,841 | 6,228 | 6,381 | |||
| Noncurrent Assets | |||||||||
| Long-term investments and receivables | 32 | 32 | 32 | 32 | 32 | 32 | |||
| Long-term investments | 32 | 32 | 32 | 32 | 32 | 32 | |||
| Total noncurrent assets: | 32 | 32 | 32 | 32 | 32 | 32 | |||
| TOTAL ASSETS: | 1,765 | 2,649 | 4,167 | 4,873 | 6,260 | 6,413 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 638 | 514 | 972 | 661 | 1,031 | 796 | |||
| Other undisclosed accounts payable and accrued liabilities | 638 | 514 | 972 | 661 | 1,031 | 796 | |||
| Deferred revenue and credits | 27 | 205 | |||||||
| Total current liabilities: | 638 | 514 | 972 | 688 | 1,236 | 796 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 638 | 514 | 972 | 688 | 1,236 | 796 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,127 | 2,135 | 3,195 | 4,185 | 5,024 | 5,617 | |||
| Common stock | 1,520 | 1,520 | 1,520 | 1,521 | 1,515 | 1,515 | |||
| Additional paid in capital | 191,917 | 191,890 | 191,863 | 191,830 | 191,797 | 191,760 | |||
| Accumulated deficit | (192,310) | (191,275) | (190,188) | (189,166) | (188,293) | (187,663) | |||
| Other undisclosed equity, attributable to parent | 5 | 5 | |||||||
| Total equity: | 1,127 | 2,135 | 3,195 | 4,185 | 5,024 | 5,617 | |||
| TOTAL LIABILITIES AND EQUITY: | 1,765 | 2,649 | 4,167 | 4,873 | 6,260 | 6,413 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2017 Q3 | 3/31/2017 Q2 | 12/31/2016 Q1 | 9/30/2016 Q4 | 6/30/2016 Q3 | 3/31/2016 Q2 | 12/31/2015 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 129 | 83 | 546 | 660 | 565 | 305 | ||
| Other undisclosed gross profit | 5 | |||||||
| Gross profit: | 129 | 83 | 551 | 660 | 565 | 305 | ||
| Operating expenses | (1,164) | (1,170) | (1,574) | (1,532) | (1,194) | (1,053) | ||
| Operating loss: | (1,035) | (1,087) | (1,023) | (872) | (629) | (748) | ||
| Interest and debt expense | (285) | |||||||
| Loss from continuing operations: | (1,035) | (1,087) | (1,023) | (872) | (629) | (1,033) | ||
| Loss before gain (loss) on sale of properties: | (1,035) | (1,087) | (1,023) | (872) | (629) | (1,033) | ||
| Net loss attributable to parent: | (1,035) | (1,087) | (1,023) | (872) | (629) | (1,033) | ||
| Preferred stock dividends and other adjustments | (1,906) | (580) | ||||||
| Net loss available to common stockholders, diluted: | (1,035) | (1,087) | (1,023) | (872) | (2,535) | (1,613) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2017 Q3 | 3/31/2017 Q2 | 12/31/2016 Q1 | 9/30/2016 Q4 | 6/30/2016 Q3 | 3/31/2016 Q2 | 12/31/2015 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,035) | (1,087) | (1,023) | (872) | (629) | (1,033) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,035) | (1,087) | (1,023) | (872) | (629) | (1,033) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.